First Commonwealth Financial Corp PA Acquires 37 Shares of Eli Lilly and Company (NYSE:LLY)

First Commonwealth Financial Corp PA increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,093 shares of the company’s stock after acquiring an additional 37 shares during the quarter. First Commonwealth Financial Corp PA’s holdings in Eli Lilly and Company were worth $1,616,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Highline Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 80.0% during the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock worth $35,000 after purchasing an additional 20 shares during the period. FPC Investment Advisory Inc. grew its position in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after buying an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company during the fourth quarter valued at about $48,000. Compass Financial Services Inc bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $50,000. Finally, Fiduciary Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $58,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 2.9 %

Shares of NYSE LLY opened at $734.85 on Thursday. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The firm’s 50-day simple moving average is $830.10 and its 200 day simple moving average is $820.95. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a market cap of $696.76 billion, a price-to-earnings ratio of 62.75, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.14% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on LLY. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research note on Friday, January 17th. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Guggenheim cut their price target on shares of Eli Lilly and Company from $973.00 to $928.00 and set a “buy” rating for the company in a research note on Monday. Finally, The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Two investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,012.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.